eli lilly - Search News

Crohn's disease, Eli Lilly

Eli Lilly Receives FDA Approval for Crohn’s Disease Treatment

Eli Lilly said it received Food and Drug Administration approval for its treatment for moderate to severely-active Crohn’s disease, an inflammatory bowel disease that causes chronic abdominal pain.

Business Insider · 5h

Eli Lilly’s Omvoh for Crohn’s disease approved by FDA

Eli Lilly (LLY) announced that the FDA has approved Omvoh for the treatment of moderately to severely active Crohn’s disease in adults. Omvoh

Reuters on MSN · 4h

US FDA approves expanded use of Lilly's bowel disease drug

Eli Lilly said on Wednesday the U.S. health regulator has approved its drug to treat adults with moderate-to-severe Crohn's disease, a type of chronic inflammatory bowel disease (IBD). The drug, branded as Omvoh,

Zepbound, Lilly and Mounjaro

STAT · 6h

Eli Lilly is considering offering more Zepbound doses in vials at lower cost

Lilly’s decision to offer vials has also been seen as its way to combat the rise in compounding. Patients have been turning to compounding pharmacies that make cheaper copies of Zepbound, since the branded treatment has been too costly and, up until recently, has been in shortage.

Barron's on MSN · 1d

Eli Lilly’s Zepbound and Mounjaro Sales Missed Estimates Again. The Wobble’s Looking Serious.

The results are an uncomfortable echo of late October 2024, when Mounjaro and Zepbound missed by similar margins. Those results unsettled investors, setting off a three-week sello

Zacks.com on MSN · 8h

NVO, VKTX Stocks Fall as Lilly's Zepbound, Mounjaro Sales Slow Down

Drops for Lilly and Big Tech Weigh on Wall Street, Even

Stocktwits on MSN · 13h

Eli Lilly Gets Wall Street Backing After Tuesday’s Turmoil, Stock Rises Premarket As Retail Stays Bullish

Eli Lilly & Co. (LLY) shares rose 0.3% premarket Wednesday, bouncing slightly after Tuesday's steep 6% plunge — the worst session for the stock in nearly four years. The selloff followed the drugmaker's disappointing fourth-quarter (Q4) revenue guidance,

Houston Chronicle · 1d

Stock market today: Wall Street mostly rises after encouraging inflation data despite Lilly's drag

Stocks got a boost from a report showing inflation at the U.S. wholesale level wasn’t as high last month as economists expected. It’s an encouraging signal ahead of a report coming Wednesday, which will show how much inflation U.

U.S. News & World Report · 1d

Stock Market Today: Drops for Lilly and Big Tech Weigh on Wall Street, Even as Most Stocks Rise

Drops for Lilly and Big Tech Weigh on Wall Street, Even as Most Stocks Rise NEW YORK (AP) — Drops for Eli Lilly and other influential companies are weighing on U.S. indexes Tuesday, even though most of the market is rising following an encouraging update on inflation.

10hon MSN

Eli Lilly CEO expects new weight loss pill to be approved next year

Eli Lilly and its rivals are working to develop more convenient options than the injectable Zepbound and Wegovy, which ...

13h

Has Eli Lilly Stock Peaked?

Eli Lilly ( LLY -6.59%) is the most valuable healthcare stock in the world, with a market capitalization of around $720 ...

STAT7h

Eli Lilly CEO on Trump, obesity drugs, and a guidance miss

In a live taping of "The Readout LOUD" at #JPM25, Eli Lilly CEO Dave Ricks talks Trump, Medicare's drug price negotiation, ...

Eli Lilly to buy Scorpion Therapeutics' cancer therapy for up to $2.5 billion

Eli Lilly said on Monday it plans to buy Scorpion Therapeutics' experimental cancer therapy for up to $2.5 billion in cash to ...

Eli Lilly: Big 2025 Ahead, But Execution Risks Exist

Eli Lilly's stock dipped due to cutting Q4 sales targets, despite a strong 2024 performance from Mounjaro and Zepbound. Click ...

Why Eli Lilly, Novo Nordisk, and Viking Therapeutics Stocks All Dropped on Tuesday

Turning to 2025 guidance, Lilly noted that new medicines and new uses of existing medicines, expansion of production, and ...

Insider Monkey1d

Why Eli Lilly (LLY) Stock Is Declining Today

The shares of pharmaceutical giant Eli Lilly (LLY) are falling 5% today after the company preannounced lower-than-expected ...

FiercePharma1d

JPM25: Eli Lilly's preliminary '24 sales figures show a continued easing in breakneck GLP-1 market

Unfortunately for the company, however, the early glimpse at its fourth-quarter performance doesn’t seem to be going over ...

14h

Eli Lilly Q4 miss brings buying opportunity, says JPMorgan

JPMorgan analyst Chris Schott says Eli Lilly’s Q4 miss represents a buying opportunity as the company is positioned for strong growth in 2025. The company’s 2025 sales guidanc ...

JD Supra10h

Lilly v. FDA: Two Stories Collide to Make this GLP-1 Case a Tale of Our Time

I recently learned of Eli Lilly & Co.’s (“Lilly”) recent lawsuit against FDA from Nicole DeFeudis, who interviewed me for her ...

Some results have been hidden because they may be inaccessible to you

Show inaccessible results

Crohn's disease, Eli Lilly

Zepbound, Lilly and Mounjaro

Drops for Lilly and Big Tech Weigh on Wall Street, Even

Related topics